The interrelationships between the pharmacokinetics of zidovudine alone and of zidovudine plus clarithromycin were evaluated with 18 volunteers with AIDS who had no infection with Mycobacterium avium complex or clinical evidence of gastroenteritis. Patients received 200 mg of zidovudine orally every 8 h on days 1 to 4 and 1,000 mg of clarithromycin every 12 h, given 2 h apart from zidovudine, on days 2 to 4. Concentrations of zidovudine in plasma were measured at steady state both prior to (phase 1, day 1) and during (phase 2, day 4) administration of clarithromycin. Levels of clarithromycin were measured at steady state on day 4. The maximum concentrations of zidovudine in plasma were significantly different in phases 1 and 2 (616.6 and 949.0 ng/ml, respectively), as were the times to the maximum concentrations of zidovudine (2.1 and 1.0 h, respectively). However, the minimum concentrations in plasma and the areas under the concentration-time curves from 0 to 6 h did not differ on days 1 and 4. There is no significant impact on the overall bioavailability of zidovudine from the addition of clarithromycin in patients with AIDS. Clarithromycin may increase the rate of zidovudine absorption, but this is unlikely to have clinical relevance.
Combinations of drugs administered to persons with AIDS are often continued for the duration of an individual's life (1-11, 16, 19, 21, 24) . Patients with AIDS may receive multiple agents that either protect against or treat Pneumocystis carinii pneumonia, cerebral toxoplasmosis, and disseminated Mycobacterium avium complex (MAC) infection. In addition, antiviral agents frequently used to treat established infections due to cytomegalovirus and antifungal agents are, on occasion, used as maintenance therapy for infections due to Cryptococcus neoformans or Candida albicans. It is important to investigate the interrelationships between these agents given to persons with AIDS, because they may influence efficacy.
Clarithromycin, a macrolide antimicrobial agent, is used to treat disseminated MAC in conjunction with other antimycobacterial agents (1, 5, 9-11, 19, 21) . In addition, clarithromycin is being studied for use as prophylaxis against MAC. Previous studies have suggested that clarithromycin may interfere with the absorption of oral zidovudine when the two agents are administered simultaneously (23) . Since zidovudine is frequently administered to persons with AIDS, the use of clarithromycin in these persons may interfere with the beneficial effects of zidovudine. The purpose of this study was to assess the pharmacokinetics of zidovudine alone and when oral doses of clarithromycin are administered 2 h apart from zidovudine.
(Results from this investigation were presented at the 10th International Conference on AIDS, Tokyo, Japan, August 1994.)
MATERIALS AND METHODS
Patients and selection criteria. The study population consisted of 20 ambulatory patients with AIDS seen in Brigham and Women's Hospital or the Harvard Community Health Plan in Boston, Mass. The study protocol was approved by the Investigational Review Board of Brigham and Women's Hospital, and each participant gave written informed consent.
Patients were considered eligible if they met the Centers for Disease Control criteria for having AIDS (4) and were able to provide written informed consent to participate. No patient was undergoing induction therapy for an acute opportunistic infection, although patients receiving maintenance therapy for cytomegalovirus retinitis or cryptococcal meningitis were enrolled. No patient had significant gastrointestinal symptoms. Three patients had chronic mild, intermittent diarrhea which had been evaluated by stool culture and radiologic studies prior to admission. No etiologic agent was identified in any of these persons; they were permitted to participate in the study because they were able to take oral medications without difficulty.
Patients were excluded if they had had a prior adverse reaction to either zidovudine or clarithromycin. Patients with documented MAC infection were also excluded.
Prior to admission, a medical history was taken, a physical examination was performed, and routine laboratory tests (serum electrolytes, blood urea nitrogen, creatinine, liver function tests, and a complete blood count with differential) were performed for each patient.
Drug administration. Patients were asked to stop all nonessential medications 3 days prior to admission. Patients receiving maintenance therapy with ganciclovir, fluconazole, or prednisone and those taking antihypertensive agents were allowed to continue these agents during their hospital stay. All study medications were administered orally with 60 ml of water. Patients received no oral medications from 30 min before to 1 h after any study medication. On days 1 through 4, patients received 200 mg of zidovudine every 8 h (0800, 1600, and 2400). On days 2 through 4, patients received 1 g of clarithromycin every 12 h, separated by 2 h from the zidovudine (0600 and 1800). Concentrations of zidovudine in plasma were measured at steady state both prior to (phase 1, day 1) and during (phase 2, day 4) clarithromycin coadministration. Patients received three doses of zidovudine before blood samples were collected on day 1. Concentrations of clarithromycin and 14(R)-hydroxyclarithromycin in plasma were measured at steady state on day 4 (phase 2).
Patients abstained from strenuous physical activity and the use of alcohol, tobacco, and stimulating beverages containing xanthine derivatives (tea, coffee, and cola drinks) from 48 h before until 24 h after the study.
Dietary restrictions. On the day of each dosing, intake of food and fluid was standardized in order to obtain a standard basal situation. Breakfast and dinner were standardized and served 1.5 h after medication (0930 and 1730). Standardized snacks were served 3.5 h after medication (1130 and 1930) .
Sample collection and analysis. Venous blood samples (5 ml) were obtained from an indwelling catheter which was inserted into the forearm. Blood samples were collected at time zero (simultaneous with zidovudine administration) and at 30 min and at 1, 1.5, 2, 3, 4, and 6 h during phase 1. During phase 2, samples were collected at time zero (simultaneous with clarithromycin administration) and at 1, 1. separated by centrifugation within 1 h of collection and stored frozen at Ϫ70ЊC until analysis. Plasma zidovudine samples were then analyzed for zidovudine concentrations by sensitive and specific radioimmunoassay procedures at Harris Laboratories (Lincoln, Nebr.). The lower limit of quantitation for zidovudine was 6.4 ng/ml, and the within-day and between-day coefficients of variation over the standard curve concentration range (6.4 to 625 ng/ml) were less than 12 and 10%, respectively. Plasma clarithromycin and 14(R)-hydroxyclarithromycin concentrations were determined by high-performance liquid chromatography at BAS Analytics (West Lafayette, Ind.) (13) . The lower limit of detection for both clarithromycin and 14(R)-hydroxyclarithromycin was 0.015 mg/liter with 1 ml of plasma, and the within-day and between-day coefficients of variation over the standard curve concentration range (0.015 to 2.0 mg/liter) were less than 7%.
Data analysis. Values for pharmacokinetic parameters were estimated by using noncompartmental techniques. Because the sampling times for zidovudine were different for the different phases of the study, only the concentrations in plasma obtained 0, 1, 2, 4, and 6 h after zidovudine administration were used in the estimation of any pharmacokinetic parameter for zidovudine. The maximum concentration in plasma (C max ), the time to C max (T max ), and the minimum concentration in plasma (C min ) were read from the observed concentration were estimated by trapezoidal summation (14) . All data are summarized as means Ϯ standard deviations. Zidovudine pharmacokinetic parameter values from phases 1 and 2 were compared via the paired t test with Procedure Univariate of SAS version 6.08 (SAS Institute Inc., Cary, N.C.). A P value of Ͻ0.05 was considered statistically significant. By using the log-transformed C max s, C min s, and AUC 0-8 values, 95% confidence intervals were constructed for the difference between the phase 2 mean (zidovudine and clarithromycin) and the phase 1 mean (zidovudine alone). These confidence intervals were obtained by using the t distribution. The endpoints of each confidence interval were then exponentiated to provide the final confidence intervals for the parameters.
RESULTS

Patient characteristics.
Twenty patients (19 males and 1 female) were enrolled in the study. Two patients were eliminated from the study after entry, as the blood samples from these patients were lost. Therefore, data from 18 subjects were available for analysis. The mean (Ϯ standard deviation) age, weight, and height for the study population were 38.7 Ϯ 6.9 years (range, 25 to 55 years), 72.0 Ϯ 10.0 kg (range, 48.5 to 107 kg), and 170.7 Ϯ 6.5 cm (range, 152 to 185 cm) ( Table 1 ). The body weights of all subjects remained relatively constant throughout the 4-day study period (mean change, Ϯ2.5%). The mean CD4 cell count was 73.2 Ϯ 62.0 cells per mm 3 (range, 7 to 280 cells per mm 3 ). The antiretroviral agents (16 patients) and chemoprophylactic agents for P. carinii pneumonia (15 patients) or MAC (4 patients) that were discontinued by each patient prior to initiation of the study are shown in Table 1 . Table 1 also lists those medications that patients continued during the study because they were required for continued treatment of established infections. These medications were intravenous ganciclovir at maintenance doses for cytomegalovirus retinitis (two patients), fluconazole for maintenance therapy for cryptococcal meningitis (two patients) or relapsing esophageal candidiasis (two patients), and prednisone for idiopathic esophageal ulceration (one patient).
Safety. All 20 patients completed the 4-day course of therapy. Clarithromycin was well tolerated at the dosage of 1,000 mg twice a day. No adverse events were reported by the 20 patients.
Pharmacokinetics. Eighteen patients were pharmacokinetically evaluable. Due to the shape of the plasma zidovudine concentration-time profiles in phase 1 for two patients, estimation of the 8-h concentration was not appropriate. Therefore, 16 patients were included in the analysis of AUC 0-8 . The mean steady-state plasma zidovudine concentration-time profiles from phase 1 (zidovudine alone) and phase 2 (zidovudine and clarithromycin) are illustrated in Fig. 1 . Zidovudine was rapidly absorbed and rapidly eliminated following oral administration. The mean zidovudine C max was significantly higher (P Ͻ 0.001) and the mean zidovudine T max was significantly shorter (P ϭ 0.005) when zidovudine was administered with clarithromycin (phase 2) than when zidovudine was administered alone (phase 1). However, the zidovudine C min and (Fig. 2) were not significantly different for the two phases (P Ͼ 0.12). A summary of the pharmacokinetic parameter values for zidovudine is shown in Table 2 .
As shown in Table 3 , the 95% confidence intervals for the log-transformed parameter values confirm that the zidovudine C max is increased when zidovudine is administered with clarithromycin and that the C min and AUC 0-8 are unchanged. If there was no change in a zidovudine parameter value due to administration of clarithromycin, the confidence interval would be expected to center around 1.0. This is true for AUC 0-8 and for C min . The confidence interval for C max , however, clearly exceeds 1.0, supporting the conclusion that the zidovudine C max is increased when zidovudine is administered with clarithromycin.
Mean steady-state concentration (in plasma)-time profiles for clarithromycin and 14(R)-hydroxyclarithromycin after the administration of 1,000 mg of clarithromycin every 12 h are illustrated in Fig. 3 . Concentrations of the parent drug in plasma were several times higher than those of the 14(R)-hydroxy metabolite. Summaries of the pharmacokinetic parameter values for both clarithromycin and its metabolite are shown in Table 4 . C max s for clarithromycin ranged from 1.3 to 9.0 g/ml, and C min s ranged from 0.3 to 6.1 g/ml.
DISCUSSION
It is important to define the pharmacokinetic interrelationship between oral agents used as part of a multidrug regimen in patients with advanced human immunodeficiency virus infection, because it may influence efficacy. Multidrug regimens are often administered to AIDS patients for the duration of their lives (1, 5, 8-11, 16, 19, 21, 24) . Zidovudine, for example, is used either as monotherapy or in combination therapy with other antiretroviral agents in patients with AIDS (8, 16, 24) . In addition, many persons with AIDS receive clarithromycin treatment (1, 5, 8-11, 16, 19, 21, 24 ) because MAC occurs in 40 to 50% of AIDS patients (6, 12, 18, 22) . Furthermore, the use of clarithromycin may be expanded if this agent proves effective as prophylaxis for MAC.
To our knowledge, two studies investigating the pharmacokinetic interrelationships between clarithromycin and zidovudine in human immunodeficiency virus-infected persons have been reported in the literature. In one, clarithromycin reduced the steady-state zidovudine concentrations by a mean of 12% (n ϭ 4) when zidovudine and clarithromycin were administered simultaneously but not when zidovudine was given 4 h or longer after clarithromycin (23) . In another study, which used a clarithromycin oral suspension (17) , various doses of clarithromycin (3.75, 7.5, or 15 mg/kg every 12 h) had no effect on the pharmacokinetics of zidovudine.
The present study demonstrates that there is no significant impact on the overall bioavailability of zidovudine from the addition of clarithromycin for patients with AIDS. The mean zidovudine C max in the phase 2 patients (receiving zidovudine plus clarithromycin) was approximately 50% higher than that in the phase 1 patients (receiving zidovudine alone). Furthermore, the mean zidovudine T max in phase 2 was approximately 50% shorter than that detected in phase 1 of this study. These results suggest an increase in the rate of zidovudine absorption when clarithromycin is administered. However, no effect on the extent of zidovudine absorption was observed, as the mean AUCs of zidovudine were not significantly different in phases 1 and 2. For this reason, it is unlikely that the changes in zidovudine levels observed in patients receiving clarithromycin would have clinical significance. Several studies have demonstrated significant variability of zidovudine levels in patients receiving fixed oral dosages of this agent. The fluctuations in zidovudine levels in patients in one trial, in fact, exceeded that observed between phase 1 and phase 2 in the present study, making it unlikely that the changes in zidovudine levels witnessed in the present study have clinical relevance. In one controlled trial, for example, steady-state concentrations of zidovudine in serum were determined for 21 patients following oral administration of 250 mg of zidovudine every 4 h after a prolonged period of time. Mean steady-state predose and 1.5 h postdose zidovudine concentrations in patients in that study were 0.16 g/ml (range, 0 to 0.84 g/ml) and 0.62 g/ml (range, 0.05 to 1.46 g/ml), respectively (Retrovir).
It is important to perform studies investigating the interaction of drugs used in patients with AIDS, as absorption may be affected by aberrations of the gastrointestinal tract, which may occur in the absence of clinical symptoms. While gastrointestinal disturbances may have been present in our patient population, they did not appear to affect the pharmacokinetics of either agent. Invasive procedures to establish the existence of histopathologic changes of the alimentary tract were not performed, as they were not clinically indicated.
The apparent increase in the rate of zidovudine absorption when zidovudine was administered 2 h apart from the clarithromycin is not easily explained. One possible hypothesis is that clarithromycin induced an increase in gastrointestinal motility in patients in this study, a phenomenon that has been reported to occur in association with the use of oral clarithromycin (Biaxin). Although no patients in the present study had gastrointestinal symptoms following clarithromycin use, they may have had an increase in gastrointestinal motility. Rapid zidovudine absorption could have occurred as a consequence of accelerated stomach emptying of zidovudine. If, in fact, the increase in motility continued beyond clarithromycin administration, a 2-h separation of the clarithromycin and zidovudine doses would not prevent an interaction between these two agents.
While clarithromycin pharmacokinetics could be studied only in the presence of the concurrently administered zidovudine, it is interesting that the values for the pharmacokinetic parameters determined in the present study are comparable to those previously reported for 1,000 mg of clarithromycin administered twice daily (15) . In that study, clarithromycin AUC values of 59 Ϯ 20.6 and 47.3 Ϯ 15.0 g ⅐ h/ml were observed when clarithromycin was administered alone and with zidovudine, respectively. These values are similar to the mean clarithromycin AUC of 47.8 Ϯ 24.0 g ⅐ h/ml estimated in our current study. A potential shortcoming of the previous study (15) was the smaller sample size (n ϭ 4) compared with that in the present study.
In the present study, four patients took fluconazole, an inhibitor of drug metabolism (20) , as maintenance therapy for fungal infections. Because clarithromycin elimination is due, in part, to metabolism (13) , concurrent administration of fluconazole may inhibit clarithromycin metabolism and increase levels of clarithromycin in plasma. Although the present study did not include measurements of concentrations of clarithromycin in plasma before and after addition of fluconazole, the plasma clarithromycin concentrations in the four patients taking fluconazole (clarithromycin AUC 0-12 , 46.5, 77.6, 36.5, and 22.5 g ⅐ h/ml) were not consistently higher than the mean plasma clarithromycin concentration in those who did not take fluconazole (clarithromycin AUC 0-12 , 48.4 g ⅐ h/ml).
In conclusion, the results of the present study suggest that there is no impairment of zidovudine absorption or elimination in patients with AIDS who receive clarithromycin when the two agents are given 2 h apart. We suspect that the changes in zidovudine levels in plasma in patients receiving clarithromycin are unlikely to have clinical relevance. These results are consistent with one previous study in which zidovudine was administered 4 h after clarithromycin (23) . The present data show no statistically significant alteration of zidovudine AUCs or C min s by clarithromycin. Although the zidovudine C max does increase and the T max does decrease with the addition of clarithromycin, we do not advocate any changes in zidovudine dose in AIDS patients who receive clarithromycin, but we recommend that clarithromycin be administered at least 2 h before or after administration of zidovudine. 
